Zentalis Announces Presentation of Positive Phase 1b Data :

Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination...

Related Keywords

San Diego , California , United States , New York , Kimberly Blackwell , Premalh Thaker , Joyce Liu , Emily White , Danielle Cantey , Division Of Gynecologic Oncology , Zentalis Pharmaceuticals , Nasdaq , Gynecological Oncology Clinical Research , Dana Farber Cancer Institute , Washington University School Of Medicine , Solebury Strategic Communications , Linkedin , Exchange Commission , Pharmaceuticals Inc , Chief Executive Officer , Safety Results , Frequent Grade , Associate Chief , Clinical Research , Gynecologic Oncology , Dana Farber Cancer , Washington University School , Board Number , Discussion Session Date , Presentation Number , Integrated Discovery Engine , Securities Litigation Reform Act , Nasdaq Zntl ,